XRTX Stock Analysis

XORTX Therapeutics Inc - Real-time stock metrics, market data, and comprehensive analysis

Loading...

Fetching stock data...

XORTX Therapeutics Inc

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.

Market Data

Current Price

$0.80

+$0.08 (11.13%)
Market Cap

-

Total Company Value
Day Range
$0.70 - $0.87
Session Volume
157.53K
Shares traded today

Valuation Metrics

P/E Ratio

-

Price ÷ Earnings
EPS (Basic)

-

Earnings Per Share
Price-to-Book

-

Market Value ÷ Book Value

Financial Health

Revenue (TTM)

-

Trailing 12 Months
Net Income (TTM)

-

Profit After Tax
Gross Margin

-

Revenue Efficiency

Returns & Dividends

Dividend Yield

-

Annual Dividend ÷ Price
Annual Dividend

-

Per Share
Payout Ratio

-

Dividend ÷ EPS

Price Performance

Price Chart
All times are in Eastern Time (ET)

Recent News

No news available

Data Source: Financial data is sourced from SEC filings via Tiingo and may be delayed. Market Status: OPEN - Prices update every 2 minutes. (Last updated: 2:24 PM)
Logos provided by Logo.dev

Contact Me

Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.

Contact Form Demo

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.